Rupee depreciation to hit SmithKline, Pfizer - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Rupee depreciation to hit SmithKline, Pfizer

Jun 13, 2000

The recent depreciation of the rupee is likely to hit mutinational pharmaceutical companies such as SmithKline Beecham and Pfizer quite adversely. This is primarily because imports not only account for a relatively larger proportion of their raw material cost but these companies also import a substantial amount (in terms of their raw material imports) of finished goods. (SmithKline actually imports its Hepatitis–B formulation Engerix from the Belgium plant of its parent.)

  Imports (Rs m)
Company Raw Material Finished goods
SmithKline Pharma 75.1 679.7
Pfizer 93.1 99.1

While the Indian companies such as Ranbaxy, Cipla and Dr Reddys should be net gainers of the rupee depreciation since their exports account for a decent proportion of their turnover, the fact remains that unless their exports account for value added formulations the foreign buyers usually insist on proportionate discounts (proportionate to the value of depreciation). The net impact would however be positive for these companies.

Company Exports
(Rs m)
(Rs m)
Exports / Sales Imports of
Raw Material
Ranbaxy 8,138.1 3,138.2 48.8% 48.4%
Dr Reddys 1,184.2 761.2 27.8% 46.0%
Cipla 1,163.5 5,520.4 18.9% 30.0%
Glaxo 761.9 683.4 8.6% 12.2%
SmithKline Beecham 190.6 760.5 5.9% 24.0%
Pfizer 67.0 201.8 2.0% 10.8%
German Remedies 59.0 11.9 9.8% 31.6%

There are also companies such as Glaxo and German Remedies, which import certain bulk drugs from their parents but they also serve as a sourcing base for the supply of older formulations to their parents. For instance Glaxo imports cefutoxamine (the bulk drug for Ceftum) from its parent but also supplies ranitidine to its parent. For these companies while the overall impact of the depreciation of the rupee would be negative it would be alleviated to some extent due to their exports.

Equitymaster requests your view! Post a comment on "Rupee depreciation to hit SmithKline, Pfizer". Click here!


More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 7, 2021 11:48 AM